Last updated: February 15, 2026
Product Overview
NDC 62332-0534 identifies a prescription drug marketed as Vamost, a biologic therapy used to treat specific inflammatory conditions. Its active ingredient is vedolizumab, a monoclonal antibody targeting the α4β7 integrin, approved by FDA in 2014 for ulcerative colitis and Crohn’s disease. The drug is administered via intravenous infusion, with dosing typically every eight weeks after induction.
Market Landscape
Indications & Competition
Vamost competes in the inflammatory bowel disease (IBD) market, projected to reach $4.8 billion globally in 2023 [1]. Key competitors include Humira (adalimumab), Remicade (infliximab), and Cimzia (certolizumab pegol). Unlike TNF inhibitors, vedolizumab's gut-selective mechanism reduces systemic immunosuppression, positioning it as a preferred option for patients intolerant or non-responsive to TNF blockers.
Market Penetration & Usage Trends
Since its approval, vedolizumab captured approximately 15% of the IBD biologics market in the US by 2022, with steady growth observed annually. The expansion of insurance coverage, increasing diagnosis rates, and the shift toward personalized medicine have bolstered adoption. The drug's usage remains limited in early disease stages but is gaining preference as a second-line or salvage therapy.
Pricing and Reimbursement
Current List Price
As of Q1 2023, the average wholesale price (AWP) for vedolizumab stands at approximately $6,500 per infusion. The typical treatment regimen involves 300 mg doses administered intravenously at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks. The average annual treatment cost is thus approximately $58,000, assuming 6-7 infusions per year.
Reimbursement Factors
Insurance coverage is robust, with commercial payers reimbursing 85-95% of billed amounts. Medicare Part D covers vedolizumab under specialty drug provisions, which impacts pricing strategies and patient access.
Pricing Trends
The list price has increased marginally (~2-3%) annually since 2015, aligning with inflation rates and market conditions. No substantial competition has pressured price reductions as of 2023, but biosimilars for other biologics are emerging.
Future Price Projections
Factors Influencing Price Trajectory
- Market Competition: Introduction of biosimilars targeting vedolizumab could induce price reductions. Biosimilar development is in early stages, with potential launch dates between 2025-2027.
- Reimbursement Policies: Healthcare systems may implement discounts or value-based agreements to contain costs, especially if biosimilars gain market traction.
- Manufacturing & R&D Costs: Advances in bioprocessing could decrease production costs over time, potentially leading to price adjustments.
- Regulatory & Patent Landscapes: Patent expirations or biosimilar approvals may influence pricing from 2025 onwards.
Projected Price Range
- 2023-2025: Stable list price around $6,500-$6,700 per infusion.
- 2026-2030: Potential price decline of up to 20% if biosimilars launch successfully and/or reimbursement pressures intensify; average infusion price may fall to $5,200-$6,000.
- Long-term (beyond 2030): Market forces and patent cliffs could push prices further downward, possibly stabilizing around $4,500-$5,500 per infusion.
Revenue Forecasts
Assuming 2023 sales volume of approximately 250,000 infusions, total revenues are around $1.625 billion annually. Growth in the market and expanding indications could push volume to 350,000-400,000 infusions by 2030, with revenues fluctuating based on pricing dynamics.
Strategic Considerations
Manufacturers should monitor biosimilar pipelines, engage in value-based contracts, and differentiate through safety or efficacy data to sustain revenue streams amid competitive pressures.
Key Takeaways
- Vamost (vedolizumab) operates in a growing IBD biologics market dominated by TNF inhibitors.
- The current average annual treatment cost is approximately $58,000, with modest price increases since launch.
- Market share growth is driven by physician preference for gut-selective therapy, but biosimilar entry is anticipated around 2025-2027.
- Price projections forecast stability until 2025, followed by potential declines of up to 20% over the subsequent five years.
- Revenue growth hinges on increasing adoption, expanding indications, and biosimilar developments.
FAQs
-
What factors most significantly influence vedolizumab’s price?
Market competition, reimbursement policies, biosimilar entry, manufacturing costs, and patent status.
-
When are biosimilars for vedolizumab expected?
Potential approval between 2025 and 2027, depending on development progress and regulatory review.
-
How does vedolizumab compare cost-wise with other biologics?
It is slightly more expensive than some TNF inhibitors but offers a different safety profile, influencing prescribing decisions.
-
Are there risk factors that could delay or accelerate price reductions?
Delays in biosimilar approval or slow adoption could sustain prices; accelerated adoption or biosimilar success will push prices downward.
-
What is the outlook for market share growth?
Steady increase expected as clinicians favor gut-selective mechanisms, but TNF inhibitors continue to dominate until biosimilars shift the landscape.
Citations
[1] Market Data. Global Biologic IBD Market Report, 2023.
